HIV and AIDS

The Challenge

After more than two decades of progress, a future free of AIDS is within reach. Efforts by communities, governments, civil society, the private sector and global health partners have resulted in extraordinary progress in the fight against HIV. Globally, new HIV infections have declined by 40%, from 2.1 million in 2010 to 1.3 million in 2024.

But HIV remains a major infectious disease and a significant threat to global health security. In 2024, 630,000 people died of AIDS-related causes, and there were 1.3 million new infections globally – around 3.5 times more than the global target of fewer than 370,000 new infections by 2025.

Adolescent girls and young women (aged 15-24 years) continue to be at high risk of HIV infection in East and Southern Africa and are much more likely to acquire HIV compared to adolescent boys and young men.

Key populations – including men who have sex with men, trans and gender diverse people, sex workers, people who use and/or inject drugs, and people in prison and other closed settings, and their sexual partners – accounted for an estimated 80% of new HIV infections outside sub-Saharan Africa and around 25% in sub-Saharan Africa in 2022.

There were still 120,000 new infections globally among children in 2024 and only 55% of the 1.4 million children living with HIV were on treatment – far below adult coverage rates.

Decreasing international funding and interconnected crises including debt distress, conflict and the erosion of human rights threaten to undo hard-won gains. Global progress hinges on bold investment, the leadership of governments, the private sector, civil society and communities, and a shared commitment to lasting impact.

HIV and AIDS by the Numbers

Funding

The Global Fund provides 26% of all international financing for HIV programs.
We have invested US$27.6 billion in programs to prevent and treat HIV and AIDS as of June 2025.
We have invested US$8.6 billion in TB/HIV programs as of June 2025.

Prevention

12.3 million people were reached with HIV prevention services in 2024.
648,000 mothers living with HIV received medicine to keep them alive and prevent transmitting HIV to their babies in 2024.

Testing and Treatment

In 2024, in countries where the Global Fund invests, 88% of people living with HIV knew their status, 79% were accessing treatment and 74% were virally suppressed.
25.6 million people were on antiretroviral therapy for HIV in 2024.
46.6 million HIV tests were taken in 2024 in countries where the Global Fund invests.
11.7 million of the HIV tests taken in 2024 were by priority and key populations.

See more HIV Data on the Data Explorer

Our Response

The Global Fund provides 26% of all international financing for HIV programs. We have invested US$27.6 billion in programs to prevent and treat HIV and AIDS and US$8.6 billion in TB/HIV programs as of June 2025.

Our investments in the fight against HIV are having an impact. As of 2024, in countries where the Global Fund invests, AIDS-related deaths had been reduced by 74% and new infections had been reduced by 62% since 2002.

Trends in AIDS-related deaths

Trends in new HIV infections

HIV burden estimates from UNAIDS, 2025 release. Estimation of “no prevention or ARVs” trends from Goals and AIM models where available. For some countries estimates of burden are not available from UNAIDS. Global Fund portfolio indicates countries that have recently received Global Fund HIV and AIDS funding and have reported programmatic results over the past two cycles.

Treatment, Care and Support

Working with partners, we are making significant progress toward reaching WHO’s “treat all” guidance and the UNAIDS “95-95-95” targets. Those efforts have significantly increased the number of people living with HIV who know their HIV status, the number of people who know their status on antiretroviral therapy and the number of people on antiretroviral therapy who have a suppressed viral load (when the amount of HIV in a person’s blood becomes so low that it is undetectable and untransmissible).

In 2024, 25.6 million people were on antiretroviral therapy for HIV in countries where the Global Fund invests. This is up from 17.5 million people in 2017, but still far from the UNAIDS 95–95–95 target of 34 million people for 2025.

We also support multi-month (three months or more of medicine or prevention products at a time) and community dispensing of HIV prevention, care and treatment products, as well as community programs for antiretroviral therapy delivery, adherence support, community leadership, engagement and treatment literacy.

Prevention

The Global Fund has steadily increased investments in HIV prevention, from US$705 million over the 2018-2020 period to nearly US$900 million for the 2024-2026 period as of July 2025.

We are investing more in high-impact HIV prevention interventions such as condoms and lubricants, pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP), and harm reduction programs for people who inject drugs. In 2024, 1.4 million people received PrEP – four times more than in 2023.

As well as these investments, we support countries to focus their efforts on locations with high HIV transmission and on people with the greatest HIV prevention needs – key populations and adolescent girls and young women, and their male sexual partners – so they have the tools, knowledge and power to prevent themselves from acquiring HIV.

We also work with partners to make HIV prevention options more accessible in spaces where people need rapid access to them. By investing in community-led monitoring, we support communities affected by HIV to monitor the accessibility, quality, acceptability and affordability of health services, so that these services are integrated and centered around the people who use them.

NextGen Market Shaping

The Global Fund is working with partners to accelerate equitable access to new or improved products for HIV prevention, testing, care and treatment. Through its NextGen Market Shaping Approach, the Global Fund has been able to generate significant cost-savings for quality-assured HIV products, including drugs and products for prevention, testing, care and treatment.

For HIV prevention, market-shaping approaches have included condoms and lubricants, products for harm reduction programs and new PrEP options, and investments to ensure last-mile supply of these tools to the people who need them.

We are also working to expand access to quality-assured, low-cost HIV rapid diagnostic tests, including self-tests, and to support countries to introduce and scale up access to the most effective HIV treatment regimens. We have also supported countries in scaling up child-friendly HIV treatments.

One area of significant progress has been in the procurement of antiretrovirals for HIV treatment. In 2000, a one-year supply of HIV treatment for one person cost more than US$10,000. By 2018 this cost had been cut to US$75, and today it is as low as US$35.

In July 2025, the Global Fund signed an access agreement with Gilead Sciences to procure lenacapavir, a long-acting injectable for HIV prevention, for low- and middle-income countries. This marks the first time in history that an HIV prevention product will be introduced in low- and middle-income countries at the same time as in high-income countries – a significant milestone for global health equity.

We have increased our investments in HIV prevention for adolescent girls and young women, focusing on 12 priority countries – Botswana, Eswatini, Kenya, Lesotho, Malawi, Mozambique, Namibia, Uganda, South Africa, Tanzania, Zambia and Zimbabwe – where HIV transmission for young women is very high.

In 2024, 2 million adolescent girls and young women in Global Fund-supported countries accessed HIV prevention services. Among these, a total of 1.28 million adolescent girls and young women were reached with HIV prevention services across the 12 priority countries.

The Global Fund/Vincent Becker

UNICEF/Dejongh

One crucial strategy in the battle against HIV is preventing transmission from mothers to babies. In 2024 in the countries where we invest, 85% of mothers living with HIV received treatment to keep themselves healthy and prevent the virus from infecting their babies, compared to only 49% in 2010.